Bharat Biotech’s ‘COVAXIN™’ Emergency Use Authorization approval by DCGI-CDSCO, MoH&FW, a significant landmark in India’s Scientific Discovery, and Scientists Capability
Dr. Krishna Ella said “The approval of COVAXIN™ for emergency use is a giant leap for Innovation and novel product development in India. It is a proud moment for the nation and a great milestone in India’s scientific capability, a kickstart to the innovation ecosystem in India. While this vaccine addresses an unmet medical need during this pandemic, our goal is to provide global access to populations that need it the most. COVAXIN™ has generated excellent safety data with robust immune responses to multiple viral proteins that persist.”
India’s biggest bio entrepreneurship platform, NBEC 2020 crowns 14 winners after an intense four-month-long competition
The winners in the student-team innovation category were Tanish T. Sridhar who won the Persistent Systems sponsored cash prize of 5 lakhs INR, Chandan Kumar Jha who won the BIRAC cash prize of 3 lakhs INR, and Abduljabbar Khan who won 2 lakhs INR in a pooled prize by K&S partners, Bioneeds and Ideaspring Capital.
Bangalore Bioinnovation Centre receives “Innovation Leadership Award”
Dr Jitendra Kumar, Managing Director of BBC said “It is an honour for team BBC to receive this award. It is great that the jury has looked into the institutions that have made the difference to the lives of others”
COVAXIN phase 2 study results & Phase-1 follow Up data
COVAXIN™ (BBV152) showed long-term antibody and T-cell memory responses (3-months after vaccination) in phase 1 volunteers, and tolerable safety outcomes with enhanced humoral & cell-mediated immune responses in the Phase 2 study.